KemPharm/$ZVRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About KemPharm
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Ticker
$ZVRA
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
59
ISIN
US4884452065
Website
KemPharm Metrics
BasicAdvanced
$492M
-
-$1.86
1.87
-
Price and volume
Market cap
$492M
Beta
1.87
52-week high
$9.62
52-week low
$4.20
Average daily volume
600K
Financial strength
Current ratio
3.024
Quick ratio
2.789
Long term debt to equity
149.302
Total debt to equity
150.737
Interest coverage (TTM)
-8.37%
Profitability
EBITDA (TTM)
-65.403
Gross margin (TTM)
78.84%
Net profit margin (TTM)
-226.64%
Operating margin (TTM)
-177.09%
Effective tax rate (TTM)
-22.06%
Revenue per employee (TTM)
$690,000
Management effectiveness
Return on assets (TTM)
-27.73%
Return on equity (TTM)
-204.78%
Valuation
Price to revenue (TTM)
10.939
Price to book
12
Price to tangible book (TTM)
-15.85
Price to free cash flow (TTM)
-7.182
Free cash flow yield (TTM)
-13.92%
Free cash flow per share (TTM)
-125.32%
Growth
Revenue change (TTM)
46.47%
Earnings per share change (TTM)
40.57%
3-year revenue growth (CAGR)
25.57%
3-year earnings per share growth (CAGR)
54.41%
10-year earnings per share growth (CAGR)
-37.07%
What the Analysts think about KemPharm
Analyst ratings (Buy, Hold, Sell) for KemPharm stock.
Bulls say / Bears say
Analysts have initiated coverage on Zevra Therapeutics with strong buy ratings and significant upside potential; for instance, Guggenheim set a price target of $21.62, indicating a 177.59% increase from the current price. (fintel.io)
Zevra's pipeline includes arimoclomol, an investigational treatment for Niemann-Pick disease type C, which has received orphan drug, Fast Track, and rare pediatric disease designations from the FDA, potentially expediting its path to market. (biospace.com)
The company reported Q4 2024 revenues of $12 million, surpassing expectations by $3.07 million, indicating strong financial performance. (marketbeat.com)
In Q4 2024, Zevra reported an EPS of -$0.67, missing consensus estimates by $0.28, which may raise concerns about profitability. (marketbeat.com)
The company's annual income stands at -$105.51 million, reflecting significant losses that could impact long-term sustainability. (barchart.com)
Zevra's stock has experienced volatility, with a 52-week high of $9.76 and a low of $4.20, indicating potential instability in investor confidence. (barchart.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jun 2025.
KemPharm Financial Performance
Revenues and expenses
KemPharm Earnings Performance
Company profitability
KemPharm News
AllArticlesVideos
Zevra Announces Final Results of 2025 Annual Meeting of Stockholders
GlobeNewsWire·1 month ago
All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees
GlobeNewsWire·1 month ago
Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for KemPharm stock?
KemPharm (ZVRA) has a market cap of $492M as of June 30, 2025.
What is the P/E ratio for KemPharm stock?
The price to earnings (P/E) ratio for KemPharm (ZVRA) stock is 0 as of June 30, 2025.
Does KemPharm stock pay dividends?
No, KemPharm (ZVRA) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next KemPharm dividend payment date?
KemPharm (ZVRA) stock does not pay dividends to its shareholders.
What is the beta indicator for KemPharm?
KemPharm (ZVRA) has a beta rating of 1.87. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.